1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S153-

  Paz Ares, L ^a   Socinski, M A ^b   Shahidi, J ^c   Hozak, R R ^c   Soldatenkova, V ^d   Thatcher, N ^e   Hirsch, F ^f  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NECITUMUMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84995775066     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30326-4     Document Type: Article

References (0)